中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
20期
1288-1292
,共5页
刘江华%于洁%张妮%王艳珍%梁绍燕%安曦洲
劉江華%于潔%張妮%王豔珍%樑紹燕%安晞洲
류강화%우길%장니%왕염진%량소연%안희주
SALL4%急性白血病%儿童%危险度%微小残留病
SALL4%急性白血病%兒童%危險度%微小殘留病
SALL4%급성백혈병%인동%위험도%미소잔류병
SALL4%acute leukemia%children%risk classification%MRD
目的：探讨婆罗双树样基因4（sal-like 4，SALL4）在儿童急性白血病中的表达及其临床意义。方法：采用实时荧光定量PCR和免疫组织化学技术检测50例初诊急性白血病患儿SALL4 mRNA及蛋白的表达量，以15例免疫性血小板减少性紫癜（immune thrombocytopenic purpura，ITP）为对照；动态观察5例白血病患儿初诊和完全缓解后SALL4 mRNA的表达变化；分析SALL4 mRNA表达量与临床指标的关系。结果：SALL4 mRNA在初诊急性B淋巴细胞白血病（B-ALL）、急性髓细胞白血病（AML）中的表达量分别为13.89（1.00～63.15）、11.12（2.31～56.59），显著高于对照组[1.00（0.29～1.71）（P<0.01）]，在急性T淋巴细胞白血病（T-ALL）中的表达量1.48（0.87～4.81）与对照组无显著差异（P>0.05）；SALL4蛋白表达检测结果与SALL4 mRNA表达结果一致；急性白血病患儿完全缓解后SALL4 mRNA表达量0.98（0.22～1.09）较初诊时[28.64（11.20～87.46）]显著降低（P<0.01）。SALL4 mRNA的高表达与外周血高白细胞计数、高危分型、诱导化疗末期微小残留病（minimal residual disease，MRD）呈正相关（r=0.424、r=0.403、r=0.393，P均<0.05）；与发病年龄，性别，肝、脾、淋巴结肿大等因素无相关性（P>0.05）。结论：SALL4可能促进了儿童B-ALL、AML的发生发展，并有望成为监测治疗效果和判断预后的新指标。
目的：探討婆囉雙樹樣基因4（sal-like 4，SALL4）在兒童急性白血病中的錶達及其臨床意義。方法：採用實時熒光定量PCR和免疫組織化學技術檢測50例初診急性白血病患兒SALL4 mRNA及蛋白的錶達量，以15例免疫性血小闆減少性紫癜（immune thrombocytopenic purpura，ITP）為對照；動態觀察5例白血病患兒初診和完全緩解後SALL4 mRNA的錶達變化；分析SALL4 mRNA錶達量與臨床指標的關繫。結果：SALL4 mRNA在初診急性B淋巴細胞白血病（B-ALL）、急性髓細胞白血病（AML）中的錶達量分彆為13.89（1.00～63.15）、11.12（2.31～56.59），顯著高于對照組[1.00（0.29～1.71）（P<0.01）]，在急性T淋巴細胞白血病（T-ALL）中的錶達量1.48（0.87～4.81）與對照組無顯著差異（P>0.05）；SALL4蛋白錶達檢測結果與SALL4 mRNA錶達結果一緻；急性白血病患兒完全緩解後SALL4 mRNA錶達量0.98（0.22～1.09）較初診時[28.64（11.20～87.46）]顯著降低（P<0.01）。SALL4 mRNA的高錶達與外週血高白細胞計數、高危分型、誘導化療末期微小殘留病（minimal residual disease，MRD）呈正相關（r=0.424、r=0.403、r=0.393，P均<0.05）；與髮病年齡，性彆，肝、脾、淋巴結腫大等因素無相關性（P>0.05）。結論：SALL4可能促進瞭兒童B-ALL、AML的髮生髮展，併有望成為鑑測治療效果和判斷預後的新指標。
목적：탐토파라쌍수양기인4（sal-like 4，SALL4）재인동급성백혈병중적표체급기림상의의。방법：채용실시형광정량PCR화면역조직화학기술검측50례초진급성백혈병환인SALL4 mRNA급단백적표체량，이15례면역성혈소판감소성자전（immune thrombocytopenic purpura，ITP）위대조；동태관찰5례백혈병환인초진화완전완해후SALL4 mRNA적표체변화；분석SALL4 mRNA표체량여림상지표적관계。결과：SALL4 mRNA재초진급성B림파세포백혈병（B-ALL）、급성수세포백혈병（AML）중적표체량분별위13.89（1.00～63.15）、11.12（2.31～56.59），현저고우대조조[1.00（0.29～1.71）（P<0.01）]，재급성T림파세포백혈병（T-ALL）중적표체량1.48（0.87～4.81）여대조조무현저차이（P>0.05）；SALL4단백표체검측결과여SALL4 mRNA표체결과일치；급성백혈병환인완전완해후SALL4 mRNA표체량0.98（0.22～1.09）교초진시[28.64（11.20～87.46）]현저강저（P<0.01）。SALL4 mRNA적고표체여외주혈고백세포계수、고위분형、유도화료말기미소잔류병（minimal residual disease，MRD）정정상관（r=0.424、r=0.403、r=0.393，P균<0.05）；여발병년령，성별，간、비、림파결종대등인소무상관성（P>0.05）。결론：SALL4가능촉진료인동B-ALL、AML적발생발전，병유망성위감측치료효과화판단예후적신지표。
Objective:To investigate the expression of sal-like 4 (SALL4) gene in children with acute leukemia and analyze its clinical significance. Methods:Real-time PCR and immunohistochemistry were used to detect SALL4 mRNA and SALL4 protein ex-pressions in 50 patients initially diagnosed with acute leukemia and in 15 patients with immune thrombocytopenic purpura (ITP), which served as controls. Changes were detected in SALL4 mRNA expression from preliminary diagnosis and after complete remission of 5 acute leukemia patients. The relationship between SALL4 mRNA expression and clinical indicators was analyzed. Results: SALL4 mRNA expression is higher in initially diagnosed B-ALL [13.89 (1.00-63.15)] and AML [11.12 (2.31-56.59)] than in ITP controls [1.00 (0.29-1.71)] (P<0.01). SALL4 mRNA expression in initially diagnosed T-ALL [1.48 (0.87-4.81)] and in controls showed no significant difference (P>0.05). SALL4 protein expression is in agreement with SALL4 mRNA expression. SALL4 mRNA expression significant-ly decreased in complete remission stage [0.98 (0.22-1.09)] than in acute phase [28.64 (11.20-87.46)] in acute-leukemia patients (P<0.01). High SALL4 mRNA expression level is positively correlated with high white blood cell count, high risk classification, and high minimal-residual disease at the end of induction chemotherapy (r=0.424, r=0.40, and r=0.393, respectively;P<0.05), but not with age, gender, hepatomegaly, splenomegaly, and lymphadenectasis (P>0.05). Conclusion:SALL4 was found to play an important role in pro-moting childhood B-ALL and AML, which promises a new target for monitoring the therapeutic effects and evaluating the prognosis of childhood B-ALL and AML.
